DEBx Medical B.V., founded in 2019, is a Dutch medical technology company dedicated to revolutionizing the management of chronic wounds by enabling their healing, thereby improving the outcomes for millions of patients. DEBx Medical aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed. DEBx core values focus on delivering affordable treatments that are easy to use and implement in daily clinical practice.
TVM Capital Healthcare’s investment in DEBx Medical will enable the company to commence commercialization of its groundbreaking product for the benefit of patients. As part of the firm’s investment, DEBx Medical will establish a regional headquarter and a production base in MENA, thereby accelerating the introduction of its innovative wound care solution to the region.
Impact Creation linked to UN SDGS
Access to Care
TVM Capital Healthcare’s investment in DEBx Medical will enable the company to commence commercialization of its groundbreaking product for the benefit of patients. As part of the firm’s investment, DEBx Medical will establish a regional headquarter and a production base in MENA, thereby accelerating the introduction of its innovative wound care solution to the region.
Quality of Care
DEBRICHEM®, has recently been featured in a 3 article supplement in the Journal of Wound Care. The articles provide an introduction to debridement with an overview of current debridement techniques and introduce DEBRICHEM® as a new option for chemical debridement, followed by a seven-patient case series from the United Kingdom. DEBRICHEM® represents a significant advancement in the field of debridement, offering a unique solution to overcome limitations associated with conventional approaches.The compelling case series encompassed seven patients with recalcitrant wounds that exhibited a lack of improvement despite receiving standard care for prolonged periods, ranging from 12 months to an astonishing 17 years. Following treatment with DEBRICHEM®, all cases displayed remarkable healing progress, characterized by a decrease in wound size, substantial resolution of slough, decrease in exudate level and robust production of granulation tissue.
Innovation
DEBx Medical, has developed a groundbreaking product, DEBRICHEM®, which offers a superior alternative to existing treatments for non-healing chronic wounds. This innovative product is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds.
Future Growth Prospects
Chronic wounds affect approximately 1-2 % of the general population in developed countries with different healing outcomes based on the wound size and etiology of the wound. Often disguised as a comorbid condition, chronic wounds represent a silent epidemic that affect a large fraction of the world’s population. The expected global value of the chronic wound care market by 2027 is 16,36 billion USD. Increasing costs of health care, an aging population, recognition of difficult-to-treat infection threats such as biofilms, and the continued threat of diabetes and obesity worldwide make chronic wounds a substantial clinical, social, and economic challenge.
